Using a methicillin-resistant Staphylococcus aureus model, a bacteria responsible for hospital-acquired infections that is resistant to treatment from a class of antibiotics called beta-lactams, which includes penicillin, researchers looked to interrupt the way the bacteria constructs the cell walls that protect it from drugs. After applying a blocker to MRSA cells that interfered with the genes that produce acid to strengthen the bacteria’s cell walls, they identified a chemically altered compound that enabled MRSA to grow normally and made 82 percent of tested strains susceptible to antibiotics.
The researchers are now seeking patents for the two molecules. The synthesis of such chemicals could be an effective strategy to combating antibiotic resistance, in addition to implementing better prescription and stewardship practices and the hundreds of millions of dollars being spent on identifying new classes of antibiotics.
More articles on infection control:
New York health department to offer free Zika testing for pregnant women
Bacterial blood streaminfection linked to 18 deaths in Wisconsin
Cleveland Clinic: First uterus transplant in US is unsuccessful
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.